Prognostic relevance of microscopic leptomeningeal dissemination has been shown for medulloblastoma patients, while stringent diagnostic criteria are lacking. In the HIT-medulloblastoma trials, CSF sampling was standardized and 2-5 cytospin preparations (from 1-2.5ml CSF) were centrally reviewed.
Both lumbar tap and ventricular CSF was considered positive, if collected at least 14 days postoperatively and if at least two single cells or one cell complex with phenotypic signs for malignancy on PAP staining were detected. CSF was considered negative, if .10 inconspicuous nucleated cells were detected from lumbar tap CSF and criteria for positivity were not fulfilled. For this analysis, 1019 CSF cytospin samples from 360 medulloblastoma patients, reviewed 2001-2007 were evaluated. 211 (¼21%) were positive. Most important impairments in cytospin quality were high rate of cytolytic alterations (n ¼ 138, 14%), and low nucleated cell count (n ¼ 39, 4%). Lumbar CSF sampling had higher sensitivity than ventricular CSF sampling (27/33 vs. 19/33, p ¼ 0.059). 11 of 24 patients with positive evaluation before d14, had negative results on d15 post-OP or later. Medulloblastoma patients with localized disease without CSF central review (n ¼ 20, 5yPFS 55 + 11%), or with insufficient quality of cytospin samples (n ¼ 27, 5yPFS 58 + 11%) had inferior outcome rates compared to M0 patients with sufficient quality, central CSF staging (n ¼ 160, 5yPFS 78 + 3%), suggesting failure in detection of M1 disease. Presence of single malignant cells or doubtful cell complexes were not associated with inferior prognosis (n ¼ 14, 5yPFS 79 + 11%). Standard recommendations for CSF sampling, processing and assessment may improve diagnostic quality and appropriate treatment stratification in clinical trials. Neuro-Oncology 18:iii97 -iii122, 2016 . doi:10.1093 
